Conclusion: ALIGN has enrolled a globally representative range of patients with IgAN. ALIGN will explore the potential benefits and risks of adding the endothelin A receptor antagonist, Atrasentan, to evidence-based therapy including RAS inhibition, in patients with IgAN and severe proteinuria who are at high risk of kidney failure. This trial is ongoing and will report results at a future date.

Heerspink H et al
WCN24-AB-2099
VA by Priya John @drpriyajohn